Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · May 14, 2023

Clinical Response to Upadacitinib and Risankizumab Is Associated With Reduced IBD Anti–TNF-α Inadequate Response Mechanisms

Inflammatory Bowel Diseases


Additional Info

Disclosure statements are available on the authors' profiles:

Inflammatory Bowel Diseases
The Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduced Inflammatory Bowel Disease Anti-TNF-α Inadequate Response Mechanisms
Inflamm. Bowel Dis. 2023 May 02;29(5)771-782, J Wang, M Macoritto, H Guay, JW Davis, MC Levesque, X Cao

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading